The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 874-880

  Gutman, David A ^a   Owens, Michael J ^a   Skelton, Kelly H ^a   Thrivikraman, K V ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 3 [6 (DIMETHYLAMINO) 4 METHYL PYRID 3 YL] 2,5 DIMETHYL N,N DIPROPYL PYRAZOLO[2,3 A]PYRIMIDIN 7 AMINE; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ANXIETY DISORDER; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEFENSIVE BEHAVIOR; DOSE RESPONSE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILIZATION STRESS; LATENT PERIOD; MALE; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; TRANQUILIZING ACTIVITY; WITHDRAWAL REFLEX; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ENDOCRINE SYSTEM; METABOLISM; PSYCHOLOGICAL ASPECT; SPRAGUE DAWLEY RAT; STRESS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CORTICOSTERONE; ENDOCRINE SYSTEM; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS;

EID: 0037289734     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042788     Document Type: Article

References (42)

1. Arborelius L, Owens MJ, Plotsky PM, and Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.
2. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, and Owens MJ (2000) Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 294:588-597.
3. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, and Lee KF (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414.
4. Berridge CW and Dunn AJ (1987) A corticotropin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice. Horm Behav 21:393-401.
5. Berridge CW and Dunn AJ (1989) Restraint-stress-induced changes in exploratory behavior appear to be mediated by norepinephrine-stimulated release of CRF. J Neurosci 9:3513-3521.
6. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, and De Souza EB (1996) Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 17:166-172.
7. Chang CP, Pearse RVD, O'Connell S, and Rosenfeld MG (1993) Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 11:1187-1195.
8. Chen C, Dagnino R Jr, De Souza EB, Grigoriadis DE, Huang CQ, Kim KI, Liu Z, Moran T, Webb TR, Whitten JP, et al. (1996) Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem 39:4358-4360.
9. Chen R, Lewis KA, Perrin MH, and Vale WW (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 90:8967-8971.
10. Cole BJ, Cador M, Stinus L, Rivier J, Vale W, Koob GF, and Le Moal M (1990) Central administration of a CRF antagonist blocks the development of stress-induced behavioral sensitization. Brain Res 512:343-346.
11. De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, and Kuhar MJ (1985) Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci 5:3189-3203.
12. Grigoriadis DE, Chen C, Wilcoxen K, Chen T, Lorang MT, Bozigian H, Liu XJ, Ling N, McCarthy JR, DeSouze EB, et al. (2000) In vitro characterization of R121919: a novel non-peptide corticotropin-releasing factor 1 receptor antagonist for the potential treatment of depression and anxiety-related disorders, in Society for Neuroscience, New Orleans, LA.
13. Grigoriadis DE, Lovenberg TW, Chalmers DT, Liaw C, and De Souze EB (1996) Characterization of corticotropin-releasing factor receptor subtypes. Ann NY Acad Sci 780:60-80.
14. Habib KE, Weld YP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, et al. (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084.
15. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, Miller AH, and Nemeroff CB (2000) Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. J Am Med Assoc 284:592-597.
16. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, and Grigoriadis DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202.
17. Heinrichs SC, Lapsansky J, Lovenberg TW, De Souza EB, and Chalmers DT (1997) Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 71:15-21.
18. Holsboer F (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiat Res 33:181-214.
19. Keck ME, Welt T, Wigger A, Renner TJ, Engelmann M, Holsboer F, and Landgraf R (2001) The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosc 13:373-380.
20. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, and Spiess J (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419.
21. Krahn DD, Gosnell BA, Grace M, and Levine AS (1986) CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res Bull 17:285-289.
22. Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Meaney MJ, and Plotsky PM (2000) Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res 122:81-103.
23. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, et al. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570-7575.
24. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, and Oltersdorf T (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain [published erratum appears in Proc Natl Acad Sci USA (1995) 92:5759]. Proc Natl Acad Sci USA 92:836-840.
25. Mansbach RS, Brooks EN, and Chen YL (1997) Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323:21-26.
26. McCarthy JR, Heinrichs SC, and Grigoriadis DE (1999) Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 5:289-315.
27. Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, and Dekeyne A (2001) Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25:585-600.
28. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, and Tomisawa K (1999) Receptor binding, behavioral and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289:926-935.
29. Owens MJ and Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473.
30. Owens MJ and Nemeroff CB (1999) Corticotropin-releasing factor antagonists in affective disorders. Opin Invest Drugs 8:1849-1858.
31. Paxinos GWC and Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
32. Primus RJ, Yevich E, Baltazar C, and Gallager DW (1997) Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropsychopharmacology 17:308-316.
33. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, et al. (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477-10482.
34. Shaham Y, Erb S, Leung S, Buczek Y, and Stewart J (1998) CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor 1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology 137:184-190.
35. Smagin GN, Harris RB, and Ryan DH (1996) Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Neurosci Lett 220:167-170.
36. Takahashi LK, Kalin NH, Vanden Burgt JA, and Sherman JE (1989) Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav Neurosci 103:648-654.
37. Thrivikraman KV, Nemeroff CB, and Plotsky PM (2000) Sensitivity to glucocorticoid-mediated fast-feedback regulation of the hypothalamic-pituitary-adrenal axis is dependent upon stressor specific neurocircuitry. Brain Res 870:87-101.
38. Thrivikraman KV and Plotsky PM (1993) Absence of glucocorticoid negative feedback to moderate hemorrhage in conscious rats. Am J Physiol 264:E497-E503.
39. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, and Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor [comments]. Nat Genet 19:162-166.
40. Vale W, Spiess J, Rivier C, and Rivier J (1981) Characterization ofa 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science (Wash DC) 213:1394-1397.
41. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, and Sawchenko PE (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428:191-212.
42. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, and Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiat Res 34:171-181.